The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population
One-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry
Andrew T.L. Ong, MBBS, FRACP,
Patrick W. Serruys, MD, PhD, FACC*,
Jiro Aoki, MD,
Angela Hoye, MBChB, MRCP,
Carlos A.G. van Mieghem, MD,
Gaston A. Rodriguez-Granillo, MD,
Marco Valgimigli, MD,
Karel Sonnenschein,
Evelyn Regar, MD, PhD,
Martin van der Ent, MD, PhD,
Peter P.T. de Jaegere, MD, PhD,
Eugene P. McFadden, MBChB, MD, FRCPI, FACC,
Georgios Sianos, MD, PhD,
Willem J. van der Giessen, MD, PhD,
Pim J. de Feyter, MD, PhD, FACC and
Ron T. van Domburg, PhD
Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands
View larger version (25K):
[in a new window]
|
Figure 1 Unadjusted Kaplan-Meier event curves at one year. (A) Cumulative risk of death. (B) Cumulative risk of death or myocardial infarction. (C) Cumulative risk of death, myocardial infarction, or target vessel revascularization. CI = confidence interval; PES = paclitaxel-eluting stent; SES = sirolimus-eluting stent.
|
|
View larger version (22K):
[in a new window]
|
Figure 2 Unadjusted one-year cumulative risk of clinically driven target vessel revascularization. Abbreviations as in Figure 1.
|
|
View larger version (29K):
[in a new window]
|
Figure 3 Hazard ratios (HR) of stent type at one-year follow-up for clinically driven target vessel revascularization in subgroups of patients according to baseline and procedural characteristics. MI = myocardial infarction; other abbreviations as in Figure 1.
|
|
|
